The IPO Buzz: French Biotech Abivax Prices NASDAQ Uplisting at $11.60 – Low End
French biotech Abivax S.A. (ABVX) priced its NASDAQ uplisting – a U.S. public offering of 18.7 million American Depositary Shares (ADS) – at $11.60 – the low end of its range – to raise $216.91 million on Thursday night (Oct. 19, 2023). The price range was $11.60 to $13.00 for the ADS. Abivax S.A.’s ADS […]
October 20, 2023 Read More